Hongyuan Pharmaceutical (SZ301246) announced on September 11 that its board of directors has appointed Xie Guanghua as the company’s Chief Financial Officer, effective immediately, to serve until the expiration of the fifth board of directors’ term. Xie Guanghua, born in June 1985, holds a bachelor’s degree and is a non-practicing Certified Public Accountant in China as well as a sponsor representative. He joined Hongyuan Pharmaceutical in August 2026. Prior to this appointment, he held positions at several accounting firms and worked in investment banking roles at Minsheng Securities and Guolian Minsheng Securities. He does not directly hold any shares in the company but has been granted 80,000 restricted shares, which have not yet vested. Former Chairman Yin Dan will no longer serve as acting Chief Financial Officer. In the first half of 2026, the company reported revenue of 1.342 billion yuan, representing a year-on-year increase of 52.05%, and a net profit attributable to shareholders of 156 million yuan, marking a turnaround from loss to profitability compared to the same period last year.
